Skip to main content

Table 2 Summary estimates of predictive performance for each model across validation cohorts

From: External validation of prognostic models predicting pre-eclampsia: individual participant data meta-analysis

Model no. Type of predictors Author (year) No. of validation cohorts Total no. of women Total events Summary estimate of performance statistic (95% CI), measures of heterogeneity (I2, τ2)
C-statistic+ Calibration slope Calibration-in-the-large
Any-onset pre-eclampsia
Trimester 1 models
  1 Clinical Plasencia 2007a 3 3257 102 0.69 (0.53, 0.81)
I2 = 1%, τ2 = 0.001
0.69 (− 0.03, 1.41)
I2 = 45%, τ2 = 0.035
0.14 (− 1.47, 1.76)
I2 = 91%, τ2 = 0.380
  2 Poon 2008 3 3257 102 0.69 (0.53, 0.81)
I2 = 3%, τ2 = 0.002
0.72 (− 0.03, 1.46)
I2 = 45%, τ2 = 0.037
0.002 (− 1.65, 1.66)
I2 = 92%, τ2 = 0.402
  3 Wright 2015a 3 1916 76 0.62 (0.48, 0.75)
I2 = 0%, τ2 = 0
0.64 (− 0.18, 1.47)
I2 = 0%, τ2 = 0
0.95 (− 1.13, 3.03)
I2 = 93%, τ2 = 0.640
  4 Clinical and biochemical markers Baschat 2014a 2 5257 287 0.71 (0.47, 0.87)
I2 = 0%, τ2 = 0
1.24 (0.00, 2.48)
I2 = 0%, τ2 = 0
− 0.43 (− 14.4, 13.55)
I2 = 98%, τ2 = 2.382
  5 Goetzinger 2010 3 6811 343 0.66 (0.30, 0.90)
I2 = 93%, τ2 = 0.315
1.124 (− 0.60, 2.84)
I2 = 76%, τ2 = 0.356
− 0.97 (− 3.04, 1.11)
I2 = 97%, τ2 = 0.667
  6 Odibo 2011a 3 59,892 1774 0.72 (0.51, 0.86)
I2 = 90%, τ2 = 0.101
1.16 (0.24, 2.08)
I2 = 93%, τ2 = 0.104
− 0.79 (− 2.62, 1.04)
I2 = 99%, τ2 = 0.511
  7 Clinical and ultrasound markers Odibo 2011b 1 1145 28 0.53 (0.39, 0.66) 0.28 (− 0.64, 1.20) − 0.52 (− 0.91, − 0.13)
Trimester 2 models
  8 Clinical and ultrasound markers Yu 2005a 1 4212 273 0.61 (0.57 to 0.65) 0.08 (0.01 to 0.14) Not estimable
Early-onset pre-eclampsia
Trimester 1 models
  9 Clinical Baschat 2014b 5 22,781 204 0.68 (0.62, 0.73)
I2 = 0%, τ2 = 0
2.04 (0.56, 3.52)
I2 = 69%, τ2 = 0.692
− 0.10 (− 1.70 to 1.49)
I2 = 97%, τ2 = 1.535
  10 Crovetto 2015a 3# 6424 21 0.58 (0.21, 0.88)
I2 = 69%, τ2 = 0.288
0.64 (− 4.01, 5.29)
I2 = 81%, τ2 = 0.217
− 0.58 (− 4.97, 3.81)
I2 = 95%, τ2 = 2.925
  11 Kuc 2013a 6 212,038 1449 0.66 (0.61, 0.71)
I2 = 32%, τ2 = 0.011
0.42 (0.29, 0.55)
I2 = 33%, τ2 = 0.004
− 4.33 (− 5.41, − 3.25)
I2 = 99%, τ2 = 0.946
  12 Plasencia 2007b 4# 6740 27 0.49 (0.43, 0.55)
I2 = 38%, τ2 = 0.005
0.51 (− 2.05, 3.08)
I2 = 0%, τ2 = 0
0.47 (− 0.80, 1.74)
I2 = 74%, τ2 = 0.452
  13 Poon 2010a 3 6424 21 0.64 (0.31, 0.87)
I2 = 34%, τ2 = 0.105
0.99 (0.02, 1.96)
I2 = 0%, τ2 = 0
− 1.09 (− 4.89, 2.70)
I2 = 93%, τ2 = 2.175
  14 Scazzocchio 2013a 3 6424 21 0.74 (0.37, 0.93)
I2 = 14%, τ2 = 0.057
0.75 (0.14, 1.36)
I2 = 0%, τ2 = 0
− 0.70 (− 3.89, 2.49)
I2 = 90%, τ2 = 1.481
  15 Wright 2015b 2 1332 9 0.74 (0.04, 1.00)
I2 = 0%, τ2 = 0
0.92 (− 4.38, 6.22)
I2 = 0%, τ2 = 0
0.28 (− 14.34, 14.90)
I2 = 90%, τ2 = 2.395
  16 Clinical and biochemical markers Poon 2009a 1 4212 10 0.74 (0.51, 0.89) 0.45 (0.21, 0.69) − 2.67 (− 3.35, − 1.99)
Trimester 2 models
  17 Clinical and ultrasound markers Yu 2005b 1 4212 10 0.91 (0.83, 0.95) 0.56 (0.29, 0.82) 2.47 (1.72, 3.23)
Late-onset pre-eclampsia
Trimester 1 models
  18 Clinical Crovetto 2015b 5 7785 384 0.63 (0.46, 0.78)
I2 = 87%, τ2 = 0.264
0.56 (− 0.01 to 1.13)
I2 = 92%, τ2 = 0.179
− 0.05 (− 1.65, 1.55)
I2 = 98%, τ2 = 1.615
  19 Kuc 2013b 8 213,532 5716 0.62 (0.57, 0.67)
I2 = 87%, τ2 = 0.025
0.66 (0.50, 0.82)
I2 = 60%, τ2 = 0.007
− 1.91 (− 2.24, − 1.59)
I2 = 98%, τ2 = 0.124
  20 Plasencia 2007c 3 3257 90 0.67 (0.54, 0.78)
I2 = 0%, τ2 = 0
0.61 (0.04, 1.18)
I2 = 14%, τ2 = 0.008
0.20 (− 1.11, 1.52)
I2 = 85%, τ2 = 0.234
  21 Poon 2010b 3 3257 90 0.65 (0.48, 0.79)
I2 = 25%, τ2 = 0.020
0.57 (0.08, 1.05)
I2 = 0%, τ2 = 0
0.12 (− 1.59, 1.84)
I2 = 91%, τ2 = 0.430
  22 Scazzocchio 2013b 1 658 26 0.60 (0.48, 0.71) 0.56 (− 0.17, 1.29) 0.52 (0.13, 0.92)
  23 Clinical and biochemical markers Poon 2009b 1 1045 13 0.68 (0.55, 0.79) 0.80 (0.26, 1.34) − 0.35 (− 0.90, 0.21)
Trimester 2 models
  24 Clinical and ultrasound markers Yu 2005c 1 4212 263 0.61 (0.57, 0.64) 0.08 (0.05, 0.15) Not estimable
  1. # Number of validation cohorts is 2 for the calibration slope as it could not be estimated reliably in SCOPE (for models 10 and 12) or POP (for model 12), and was therefore excluded from the meta-analysis. + The C-statistic was pooled on the logit scale, therefore I2 is for logit(C-statistic).